Analyst Ami Fadia from Needham reiterated a Buy rating on Atai Beckley N.V. and keeping the price target at $14.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ami Fadia has given his Buy rating due to a combination of factors related to BPL-003’s emerging profile in treatment-resistant depression. She highlights the drug’s potential for sustained benefit, an improved safety profile versus current standards of care, a more practical dosing regimen, and the opportunity to plug into the existing Spravato treatment infrastructure, all of which could support differentiated positioning in the market.
In addition, Fadia underscores that key opinion leaders currently view short-acting psychedelic therapies favorably, management believes BPL-003 could justify a price above Spravato’s current U.S. wholesale acquisition cost, and the intellectual property estate offers protection into the 2040s. With clinical and pipeline milestones reaffirmed and her model updated to reflect these dynamics, she maintains a constructive outlook on ATAI and reiterates a Buy recommendation.